NTLA logo

NTLA
Intellia Therapeutics Inc

14,359
Mkt Cap
$1.64B
Volume
1.43M
52W High
$28.25
52W Low
$6.65
PE Ratio
-3.61
NTLA Fundamentals
Price
$13.83
Prev Close
$13.87
Open
$13.73
50D MA
$13.06
Beta
1.74
Avg. Volume
4.36M
EPS (Annual)
-$3.81
P/B
2.40
Rev/Employee
$179,498.67
$617.75
Loading...
Loading...
News
all
press releases
Take the Zacks Approach to Beat the Markets: LiveOne, Micron, Clorox in Focus
LVO, MU and CLX highlight how Zacks strategies and portfolio picks are delivering strong gains despite recent market volatility.
Zacks·18d ago
News Placeholder
More News
News Placeholder
Hudson Bay Capital Management LP Sells 235,000 Shares of Intellia Therapeutics, Inc. $NTLA
Hudson Bay Capital Management LP lowered its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 50.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned...
MarketBeat·19d ago
News Placeholder
Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus
ALLO, SBUX and AMGN highlight how Zacks strategies and portfolio picks are delivering strong gains despite recent market volatility.
Zacks·1mo ago
News Placeholder
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen
Wall Street Zen upgraded shares of Intellia Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·1mo ago
News Placeholder
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Brokerages
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have received an average recommendation of "Hold" from the twenty-one analysts that are presently covering the stock, Marketbeat...
MarketBeat·1mo ago
News Placeholder
ARK Investment Management LLC Trims Stake in Intellia Therapeutics, Inc. $NTLA
ARK Investment Management LLC lessened its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 8.4% in the third quarter, according to the company in its most recent filing with...
MarketBeat·1mo ago
News Placeholder
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at JonesTrading
JonesTrading raised Intellia Therapeutics from a "hold" rating to a "buy" rating and set a $29.00 price objective for the company in a research report on Wednesday...
MarketBeat·1mo ago
News Placeholder
Intellia Therapeutics (NASDAQ:NTLA) Given New $48.00 Price Target at Canaccord Genuity Group
Canaccord Genuity Group cut their price objective on shares of Intellia Therapeutics from $54.00 to $48.00 and set a "buy" rating on the stock in a research report on Tuesday...
MarketBeat·1mo ago
News Placeholder
Leerink Partners Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price
Leerink Partners lifted their price target on shares of Intellia Therapeutics from $27.00 to $29.00 and gave the company an "outperform" rating in a research note on Tuesday...
MarketBeat·1mo ago
News Placeholder
Royal Bank Of Canada Issues Positive Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price
Royal Bank Of Canada lifted their price target on shares of Intellia Therapeutics from $9.00 to $15.00 and gave the company a "sector perform" rating in a research report on Tuesday...
MarketBeat·1mo ago
<
1
2
...
>

Latest NTLA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.